Search Results
Aug 13, 2026, 10:31 ET Bronchiectasis Market is Expected to Surge at a CAGR of 15% by 2036, Owing to the Launch of DPP1/CatC Inhibitors, Therapeutic Phage Cocktails, Nebulized Mucoactive Agents, and Other Novel Mechanisms | DelveInsight
Research Collaboration (EMBARC) announced at the World Bronchiectasis Conference (WBC 2026) its planned collaboration with Insmed to assess brensocatib 25 mg, an oral and reversible dipeptidyl peptidase-1 (DPP-1) inhibitor. In May 2026, Infex Therapeutics reported encouraging findings from its
More news about: DelveInsight Business Research, LLP
Aug 13, 2026, 08:05 ET Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
harness the body's natural machinery to selectively degrade, rather than inhibit, disease-causing proteins. The recommended dosage of VEPPANU is 200 mg taken orally once daily. VEPPANU is immediately available through Rigel's network of specialty distributors and specialty pharmacies in the United States
More news about: Rigel Pharmaceuticals, Inc.
Aug 13, 2026, 07:30 ET Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
presentations and publication of the SENTRY results in the Journal of Clinical Oncology.Continue enrolling patients into the 40 mg cohort of the Phase 2 SENTRY-2 trial (
More news about: Karyopharm Therapeutics Inc.
Aug 12, 2026, 08:30 ET Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
included a four-week screening period, a 24-week treatment period during which participants received 40 mg of INGREZZA once-daily for the first four weeks, followed by flexible dosing of 40 mg, 60 mg or 80 mg once-daily based on individual treatment needs and a two-week safety follow-up period. Baseline socio-demographic
More news about: Neurocrine Biosciences, Inc.
Aug 12, 2026, 05:59 ET Apotex Announces First Quarter 2027 Results
for chronic weight management in Canada. Sevmia (semaglutide injection) is supplied as a multi-use pre-filled pen delivering doses of 1 mg (4 mg per pen; 1.34 mg/mL). The approval expands the Company's semaglutide portfolio and positions Apotex to participate in the growing obesity treatment market while
More news about: Apotex Health Corp.
Aug 11, 2026, 10:19 ET Upstate Elevator Launches First Dual Kanna & Kava Beverage Line
flavor, formulated with noble kava root and L-theanine to promote a positive mood and light, social energy. Made with 50mg Zembrin® kanna, 20mg kava extract, 90mg L-theanine, and 40mg potassium, it's 40 calories and low sugar. Bright, refreshing, and easy to sip, it keeps things light and open for afternoons,
More news about: Upstate Elevator
Aug 11, 2026, 09:01 ET Neurolief Expands Veterans' Access to Prescription Neuromodulation for Depression and Migraine Through New VA Contract
for remote monitoring.About Relivion MGRelivion MG is an FDA-cleared and CE-marked brain neuromodulation
More news about: Neurolief Inc.
Aug 11, 2026, 09:01 ET Neurolief Expands Veterans' Access to Prescription Neuromodulation for Depression and Migraine Through New VA Contract
for remote monitoring.About Relivion MGRelivion MG is an FDA-cleared and CE-marked brain neuromodulation
More news about: Neurolief Inc.
Aug 10, 2026, 16:43 ET Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
KSI-501 5 mg compared with intravitreal aflibercept 2 mg in patients with visual impairment secondary to center-involved DME.Approximately 910 patients, treatment-naïve or previously treated, will be randomized 5:3:5 to one of three arms:Arm A: KSI-501 5 mg every 8
More news about: Kodiak Sciences Inc.
Aug 10, 2026, 16:02 ET Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
presented new clinical data from an ongoing Phase 1b study of BHV-1300 in patients with Graves' disease. In the study, weekly administration of BHV-1300 1000 mg subcutaneously achieved mean reductions of pathogenic TSHR-IgG1 autoantibodies of greater than 80% by week 12 in patients with Graves' hyperthyroidism.
More news about: Biohaven Ltd.
Aug 10, 2026, 08:34 ET OmniActive's Zenroot, Root-Only Ashwagandha Extract Is Now USP Verified
Ingredient Verification Program for Dietary Ingredients. Zenroot is the only USP Verified root-only ashwagandha extract with a low daily dose of 125 mg. The milestone comes as the ashwagandha category continues to expand, and brands face greater expectations around sourcing, safety, testing, and
More news about: OmniActive Health Technologies
Aug 10, 2026, 08:24 ET Bayer leva tecnologia e logística a agricultores familiares para fortalecer a produção de algodão no Norte de Minas
de Difusão de Tecnologia Algodoeira de Catuti (Ceditac), a Bayer e parceiros da cadeia promoveram um dia de campo no Sítio Custódio, em Monte Azul, MG. O evento demonstrou como a transferência de conhecimento agronômico de ponta impulsiona a transformação social e econômica da agricultura familiar. A
More news about: Bayer
Aug 10, 2026, 03:00 ET Seegene propose une approche globale de dépistage des infections de l'appareil génital dans le cadre de la Global Million Clinical Study (GMCS)
cibles des tests de dépistage d'ISTChlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Mycoplasma genitalium (MG), Trichomonas vaginalis (TV), Mycoplasma hominis (MH), Ureaplasma urealyticum (UU), Ureaplasma parvum (UP), virus de l'herpès
More news about: Seegene Inc.
Aug 09, 2026, 21:08 ET KT&G Launches Global Brand ESSE at Istanbul Airport Duty-Free
as KT&G's flagship global brand.The product lineup introduced at Istanbul Airport consists of five variants:ESSE Blue, ESSE Change 4mg, ESSE Himalaya, ESSE Double Shot, ESSE Change Double Orange.Istanbul Airport ranks among the world's top airports by annual passenger volume,
More news about: KT&G Corporation
Aug 09, 2026, 20:51 ET KT&G Launches Global Brand ESSE at Istanbul Airport Duty-Free
as KT&G's flagship global brand.The product lineup introduced at Istanbul Airport consists of five variants:ESSE Blue, ESSE Change 4mg, ESSE Himalaya, ESSE Double Shot, ESSE Change Double Orange.Istanbul Airport ranks among the world's top airports by annual passenger volume,
More news about: KT&G Corporation
Aug 07, 2026, 08:45 ET Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
ER+/HER2- Breast Cancer (EVANGELINE)," the Company described EVANGELINE (NCT05607004), an ongoing, multicenter, open-label Phase 2 study evaluating daily 40 mg (Z)-endoxifen plus goserelin administered every 28 days as neoadjuvant therapy in premenopausal women with ER+/human epidermal growth factor receptor
More news about: Atossa Therapeutics Inc
Aug 07, 2026, 07:02 ET 禮邦醫藥AP301新藥上市申請獲國家藥監局受理
組血清磷較基線降幅的最小平方均值（LSM）為0.72mmol/L（2.22 mg/dL），碳酸司維拉姆組為0.70mmol/L（2.17 mg/dL），兩組降幅差值的95%置信區間（CI）上限（0.06 mmol/L〔0.20 mg/dL〕）低於預設非劣界值0.19mmol/L（0.59 mg/dL），即AP301的降磷效果達到研究預設的非劣效標准。[4]於低劑量對照期（第24周末至第27周末），在AP301治療應答者（第20周末血清磷<1.78 mmol/L〔5.5 mg/dL〕）中按1:1再隨機分配，AP301維持劑量組（94名）的血清磷控制優於AP301無效低劑量對照組（93名），組間差值為−0.58 mmol/L（−1.8
More news about: 禮邦醫藥
Aug 07, 2026, 06:34 ET Alebund's AP301 NDA Accepted for Review by China's NMPA
mmol/L ([2.22 mg/dL] vs. 0.70 mmol/L [2.22 mg/dL] vs. 0.70 mmol/L [2.17 mg/dL], respectively); the upper bound of the 95% confidence interval (CI) for the between-group difference (0.06 mmol/L [0.20 mg/dL]) was below the pre-defined non-inferiority margin of 0.19 mmol/L (0.59 mg/dL), demonstrating
More news about: Alebund Pharmaceuticals
Aug 06, 2026, 19:59 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Erasca, Inc. of Class Action Lawsuit and Upcoming Deadlines - ERAS
after market hours on April 27, 2026, Erasca reported preliminary Phase 1 clinical data for ERAS-0015 and disclosing that one patient that received 24 mg of ERAS-0015 had died approximately a month after starting ERAS-0015. The patient was classified as a "Grade 3 TRAE of pneumonitis" that "progressed
More news about: Pomerantz LLP
Aug 06, 2026, 17:05 ET Loma Negra Reports 2Q26 results
1.5 %Adjusted EBITDA Mg.20.2 %
More news about: LOMA NEGRA
Aug 06, 2026, 16:05 ET MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update
the highest planned dose levels of 48 mg and 64 mg, representing an important execution milestone as we prepare for our 16-week topline data readout, expected in the fourth quarter of 2026. Also of note, during the quarter, we presented additional data from our 48 mg Phase 1 study of DA-1726 at both the
More news about: MetaVia Inc.
Aug 06, 2026, 07:30 ET Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).ILD/pneumonitis led to dose interruption
More news about: Nuvation Bio, Inc.
Aug 06, 2026, 07:00 ET Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
was 2.5%, 4.1%, and 4.0% in patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively. Skin CancersIn ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in placebo-treated patients. AlopeciaIn
More news about: Insmed Incorporated
Aug 06, 2026, 07:00 ET Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026
enrolling.About PEAK and PINNACLEThe PEAK and PINNACLE studies are superiority studies evaluating two dose levels of KSI-101 (5 mg and 10 mg) compared to sham treatment in patients with MESI. PEAK and PINNACLE are identical in study design with key differences in patient population. PEAK
More news about: Kodiak Sciences Inc.
Aug 06, 2026, 06:59 ET Viatris Reports Second-Quarter 2026 Financial Results
million. In June, the FDA approved the Company's generic ferric carboxymaltose injection in three strengths: 750 mg/15 mL, 1000 mg/20 mL and 100 mg/2 mL. Ferric carboxymaltose is a substitutable generic version of Injectafer®, which is indicated for the treatment of iron
More news about: Viatris Inc.